Biological E. Limited and Recbio Collaborate to Produce HPV9 Vaccine
Chinese biopharmaceutical company Recbio Technology and Indian vaccine company Biological E. Limited have signed an agreement to transfer technology for the production of the HPV9 vaccine. The vaccine is designed to protect against nine types of Human Papillomavirus (HPV) that can lead to various cancers and genital warts. This collaboration aims to make the vaccine accessible and affordable globally.
Jiangsu Recbio Technology Company, a Chinese biopharmaceutical company, has entered into a licensing cooperation agreement with Hyderabad-based vaccine and pharma company Biological E. Limited (BE) to transfer their recombinant 9-valent HPV (HPV9) vaccine technology. Recbio will provide BE with drug substance and technology for vaccine formulation, filling, and packaging. BE will have exclusive rights to commercialize the vaccine in India and participate in tenders in other markets.
The HPV9 vaccine is designed to protect against nine types of Human Papillomavirus (HPV) that can cause various cancers and genital warts. Cervical cancer, linked to HPV infections, is a significant cause of cancer-related deaths among women globally. Preventive vaccination is crucial in reducing the burden of HPV-related cancers.
REC603, Recbio's core product, is currently in Phase III clinical trials in China for individuals aged 9 to 45. BE plans to start large-scale manufacturing of the HPV9 vaccine after completing the technology transfer. Both companies aim to make the vaccine accessible and affordable globally to improve public health.
According to the source: Deccan Chronicle.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
